The purpose of this pilot clinical trial is to confirm the efficacy and safety of Nexpowder™ for hemostasis in pilot cohort of patients with NVUGIB in Singapore
24 subjects with non variceal bleeding will be enrolled. The efficacy and safety of Nexpowder™ as primary technique of endoscopci hemostasis will be assessed in this pi,ot study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
Endoscopic hemostasis
Changi General Hospital
Singapore, Singapore
RECRUITINGendoscopic hemostasis
endoscopic hemostasis success rate
Time frame: up to 24 hours
recurrent bleeding rate on second-look endoscopy
recurrent bleeding rate on second-look endoscopy
Time frame: 24 hours
hydrogel persistence rate at the bleeding site
hydrogel persistence rate at the bleeding site
Time frame: 24 hours
Recurrent bleeding within 30 days after endoscopic therapy
Recurrent bleeding within 30 days after endoscopic therapy
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.